Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EBT: 2020-2024

Historic EBT for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to -$115.6 million.

  • Tarsus Pharmaceuticals' EBT rose 46.00% to -$12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.0 million, marking a year-over-year increase of 38.99%. This contributed to the annual value of -$115.6 million for FY2024, which is 14.97% up from last year.
  • As of FY2024, Tarsus Pharmaceuticals' EBT stood at -$115.6 million, which was up 14.97% from -$135.9 million recorded in FY2023.
  • In the past 5 years, Tarsus Pharmaceuticals' EBT registered a high of -$13.8 million during FY2021, and its lowest value of -$135.9 million during FY2023.
  • Moreover, its 3-year median value for EBT was -$115.6 million (2024), whereas its average is -$104.5 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' EBT surged by 48.63% in 2021 and then plummeted by 350.88% in 2022.
  • Yearly analysis of 5 years shows Tarsus Pharmaceuticals' EBT stood at -$26.8 million in 2020, then soared by 48.63% to -$13.8 million in 2021, then tumbled by 350.88% to -$62.1 million in 2022, then crashed by 118.85% to -$135.9 million in 2023, then climbed by 14.97% to -$115.6 million in 2024.